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Nanoparticles have shown promise as both drug delivery vehicles and direct antitumor systems,
but they must be properly designed in order to maximize efficacy. Computational modeling is
often used both to design new nanoparticles and to better understand existing ones. Modeled
processes include the release of drugs at the tumor site and the physical interaction between the
nanoparticle and cancer cells. In this article, we provide an overview of three different targeted
drug delivery methods (passive targeting, active targeting and physical targeting), compare
methods of action, advantages, limitations, and the current stage of research. For the most
commonly used nanoparticle carriers, fabrication methods are also reviewed. This is followed by a
review of computational simulations and models on nanoparticle-based drug delivery.

targeted drug delivery; self-assembly of nanoparticles; nanoparticle design; cancer; multiscale
modeling

1. Introduction

Author Manuscript

Nanoparticles (NPs) often exhibit different magnetic, thermal, optical and electrical
properties due to their high surface area and limited quantum-mechanical effects 1. NPs are
often developed and used as drug carriers, as they can deliver chemotherapeutics targeted to
the tumor tissue without damaging normal organs (Fig. 1). The ideal NP carriers should be
biodegradable, stable, non-immunogenic, easy to fabricate, cost effective, and able to release
their payloads only at the target site 2.
Medical NPs are often manufactured with a guided bottom-up method, in which engineered
macromolecular components are guided by external stimuli to interact with each other and
self-assemble into complex structures that otherwise would not be possible 3. Drugs can
either be encapsulated within the nanoparticle or attached to surface.
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A typical drug delivery nanoparticle starts with a nanoplatform class, which include
liposomes, polymeric micelles, drug conjugated polymers, and dendrimers, among
others 4–7. There are three main methods to transport drug-loaded nanoparticles to diseased
sites: passive targeting, active targeting, and physical targeting. Passive targeting works
through the increased permeability and retention (EPR) effect, which makes tumor cells
preferentially absorb NP-sized bodies 8,9. In active targeting, NPs are functionalized with
ligands such as antibodies, proteins, and peptides 10, which interact with receptors
overexpressed at the target site 11. Physical targeting uses external sources or fields to guide
NPs to the target site and to control the release process, for example in photothermal and
magnetic hyperthermia therapy. For all targeting types, drug release can be triggered by a
change in pH, temperature, or a combination of both.

Author Manuscript

In order to design an effective NP, one needs to understand the combinatorial effects of size,
shape, surface chemistry, patient-specific information, and other parameters. Optimizing all
of these parameters through experiments is both time and resource-intensive, and so
computational modeling is used to shrink this possibility space. Simulations have been used
to model the continuum of NP transport and the quantum mechanical interactions of ligand
receptors. Mesoscale modeling and Monte-Carlo simulations are also often used when
certain values are uncertain 12.
The aim of this paper is to review fabrication methods for the most common nanoparticle
types (specifically self-assembly), targeted drug delivery processes, and the current state of
NP computational modeling. Directions for future research are also discussed.

2. Self-assembled nanoparticles as delivery vehicles
Author Manuscript

Medical nanoparticles, despite their name, are far from the smallest things that scientists and
engineers work with. Rather, they occupy a manufacturing blind spot located between large
and small structures. Objects and materials with features at, and larger than, the microscale
are now readily fabricated through “top-down” approaches like lithography and precision
machining. Objects smaller than nanoparticles are generally easily synthesized through
“bottom-up” methods in which individual chemicals essentially assemble themselves under
the influence of intermolecular forces. Nanoparticles are too large and complex to be made
by simply mixing their molecular components in a test tube, but much too small to be
assembled with even the highest precision lithographic device. The solution is a guided
bottom-up approach, in which macromolecular components are engineered to interact with
each other and often external stimuli fields and self-assemble into structures more complex
than would otherwise be possible 3.

Author Manuscript

While there are many types of self-assembled nanoparticles, the most studied can broadly be
sorted by structure. Below is an introduction, with examples, to amphiphilic NPs (the most
common type of drug carrying NP), followed by a brief explanation of other novel NP
structures: dendrimers, polyrotaxanes, functionalized carbon nanotubes, graphene, and metal
solid-core nanoparticles. It is important to note that all of these NPs can be functionalized to
actively target specific sites in and on tumor cells.
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2.1 Amphiphilic Nanoparticles
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The earliest drug NPs were biomimetic in nature, mimicking the micelles and liposomes
already present in the body. These NPs contain macromolecules with both hydrophobic and
hydrophilic regions. In an aqueous environment such as blood or cellular fluid, the
hydrophobic regions will cluster together in order to be shielded from the surrounding polar
water, forming a micelle. Synthetic micelles have hydrophobic cores, while more complex
amphiphiles can form full liposomes with a double-layered macromolecular wall and a
hydrophilic core with the same or different properties as the surrounding fluid (Fig. 2).
Drugs can be captured either in the core or on the surface of these particles, depending on
their hydrophobicity. In either case, the drug is shielded from removal by the immune
system and from other in vivo hazards.

Author Manuscript

An early example of micelle-forming particles involved poly(ethylene oxide)-poly(aspartic
acid) block copolymers (PEO-PAA) 13. These polymers were used to create a selfassembling micelle containing the chemotherapy drug doxorubicin (DOX). DOX is
commonly used to test the efficacy of self-assembling carriers, and comes in both
hydrophobic and hydrophilic HCl formulations – it can be assumed to be hydrophobic
unless stated otherwise. In this case, DOX was bound to the hydrophobic PAA polymer in
organic solvent and then pushed through a membrane into an aqueous solution, a technique
known variously as membrane dialysis or diafiltration. This transition from hydrophobic to
hydrophilic solution induces the formation of micelles and leaves DOX encapsulated at the
PAA center. The resulting nanoparticle was extremely soluble and stable in water, increasing
the half-life of the payload drug.

Author Manuscript

A similar experiment was carried out with an amphiphilic pullulan acetate polymer 14.
Cancer cells have been shown to overexpress vitamin H, so the polymer was functionalized
with it in order to actively target these cancer cells. After DOX was loaded into the micelles
using membrane dialysis, the authors found that the amount of vitamin H expressed on the
surface of the nanoparticle correlated with its uptake by cancer cells, indicating successful
active targeting.

Author Manuscript

More complex micelles can be engineered to release their payloads in response to external
stimulation. Bae et al. 15 had designed pH-sensitive nanoparticle carriers which follows
previous reports on poly(ethylene glycol)-poly(aspartate-hydrazone) copolymers. DOX was
bound to the hydrazone group and micelles were again formed through membrane dialysis.
Hydrazone bonds are easily cleaved in acidic conditions, so this micelle was designed to
expose DOX in response to low pH. Micelles are taken up by cells through endocytosis and
subsequently engulfed by lysosomes, which have a pH of around 5 and thus trigger drug
release. The authors found that DOX concentration decreased as a function of pH, with
around 30% of the drug released at a pH of 5 and the entire payload released at lower pH.
A particularly interesting trigger-based nanoparticle was created by combining the pH
responsive polymer poly(acrylic acid) (PAA) with the heat sensitive poly(Nisopropylacrylamide) (PNIPAM) 16. PNIPAM becomes hydrophobic above its lower critical
solution temperature of around 32°C, while PAA becomes hydrophobic at a pH below 4.8.
The copolymer will thus form a micelle with a PNIPAM core at high temperature and pH,
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but flip to a PAA core at low temperature and pH. PAA also binds to DOX in aqueous
solution, eliminating the need for organic solvents or membrane dialysis. When it binds at
low temperature and high pH, the PAA-DOX complex becomes hydrophobic and forms
micelles. This nanoparticle was shown to exhibit drug release both with an increase in
temperature (which causes the micelle to flip inside-out and expose DOX to the
environment) and a drop in pH (which causes PAA to protonate and release the less positive
DOX). PNIPAM has also been used to synthesize nanoparticles that can shrink in volume in
response to temperature 17.

Author Manuscript

Polymer nanoparticles have also been made with hybrid polymer-lipid amphiphiles, which
allow for a broader range of potential polymers. This system was used in a nanoparticle able
to hold both drugs and DNA using a cationic core-shell system 18. The main polymer chain
is hydrophilic poly(N-methyldietheneamine sebacate) (PMDS) grafted with the hydrophobic
N-(2-bromoethyl) carbarmoyl cholesterol lipid to form an amphiphilic copolymer. The
antitumor drug Paclitaxel (PTX) was encapsulated through membrane dialysis, and
luciferase-coding DNA was bound to the nanoparticle in order to detect fluorescence. It was
found that cancer cells successfully expressed luciferase, indicating successful endocytosis.
Lipids can also be used as a molecular shield to increase drug half-life in blood 19.
It is also possible to change the chemistry of certain polymers to distort the resulting
nanoparticle 20. Micelles can be created in a variety of non-spherical shapes using
poly[oligo(ethyleneglycol)methacrylate]-block-[poly(styrene)-copoly(vinyl benzaldehyde)]
block polymers. The shape of the micelles changed from sphere to rod as the degree of
polymerization for the P(ST-co-VBA) blocks increased. DOX was able to be loaded into the
micelles as normal.

Author Manuscript

Huang et al. 21 designed a poly(lactide-co-glycolic acid) nanoparticle coated with sgc8
aptamer capable of carrying both a hydrophobic and hydrophilic cancer drug. After selfassembly, hydrophilic DOX is located in the poly(ethylene-glycol) shell and hydrophobic
paclitaxel is located in the PLGA core. The sgc8 aptamer causes the nanoparticle to be
internalized by cancer cells specifically, an example of active targeting. The authors show
that the multidrug combo was more effective than either drug individually at reducing cell
viability, and the addition of a second drug had an insignificant effect on the viability of
normal cells. It is also possible to use transferrin on the nanoparticles to increase uptake by
cancer cells 22.

Author Manuscript

Xia et al. 23 designed silk-elastin protein polymer nanoparticles. Silk-elastin-like proteins
are synthetic genetically engineered proteins designed to mimic the properties of both silk
and elastin. The proteins are temperature-dependent amphiphiles and will form micelles. In
this case, it was shown that DOX actually triggered micelle formation in some cases by
increasing the hydrophobicity of the silk-end chains. The authors reason that this polymer
and method of self-assembly, since it is formed biologically in non-extreme environments,
will generate fewer toxins and be a safer alternative to traditional methods.
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2.2 Novel Nanoparticle Structures

Author Manuscript

An example of a novel nanoparticle structure is a dendrimer, which is a repeatedly branching
nanostructure that mimics the structure of tree branches and blood vessels 7. This shape is
shown to both generate large surface areas and disperse a surface more evenly throughout
the structure. Dendrimers are commonly made of poly(amidoamine), but can also be made
from other polymers. It has been shown that dendrimers can be used to target cancer cells
with high accuracy 26. Lam et al reported a novel class of micelles made of linear PEG and
dendritic cholic acids (CA) block copolymers (called telodendrimers) 27. By crosslinking the
boronate esters at the core-shell interface, the stability of these micelles can be improved
(Fig. 4) 28. As the crosslinking reactants, boronic acid and catechol were added to the
polymers through step-wise peptide chemistry.

Author Manuscript

Rotaxanes are molecular linkages in which a cyclic molecule encircles a dumbbell-shaped
one – the cyclic molecule can rotate but cannot slide off of the dumbbell. Polyrotaxanes can
be a useful tool for drug delivery 29. Liu et al. attached cyclic cyclodextrin to poly(ethylene
glycol) chains in order to form a nanoparticle. Hydrophobic cinnamic acid was attached to
the ends of the PEG chains in order to increase the space between the cyclodextrin rings,
providing space for DOX to bind. This system can also be used to transport the drug
methotrexate 24.

Author Manuscript

Dendrimers and Rotaxanes are used primarily for drug delivery, but the next three structures
are also often used in thermal therapy, where a localized temperature increase is used to
destroy a tumor. Graphene is a single atom-thick hexagonal allotrope of carbon with novel
electrical, thermal, and mechanical properties. Because of its high surface area, it is useful as
a drug carrier, and its structure makes it efficient at converting infrared light into heat. It is,
however, relatively toxic, and must be stabilized and shielded through the addition of
polymers to its surface 25,30. Carbon nanotubes are rolled tubes of graphene that exhibit
many of the same properties. Nanotubes have been used as hybrid drug carries, where the
antitumor drug is released only in a specific site when bombarded with near-infrared
radiation and the NPs are heated up. This can help to limit drug release to the tumor site and
protect healthy tissue 31,32.
Metal-core nanoparticles can be used photothermally, like graphene and carbon nanotubes,
but they can also be used for magnetic hyperthermia, where a magnetic NP oscillates and
heats up in response to an external magnetic field. Most NPs are made of magnetite or
maghemite cores, and are relatively biocompatible. Successful clinical trials have also been
done with a magnetic fluid composed of dispersed NPs in water 33.

Author Manuscript

Oligopeptides have been extensively studied as nanocarriers due to their intrinsic pH
sensitivity resulting from amino acids. Zhang et al. developed a liposome system based on
zwitterionic oligopeptide lipids as nanocarriers 34. The amino acid-based lipids, 1,5dioctadecyl-L-glutamyl 2-histidylhexahydrobenzoic acid (HHG2C18) and 1,5-distearyl N(N-α-(4-mPEG2000) butanedione)-histidyl-L-glutamate (PEGHG2C18), have a multistage
pH-response to the tumor microenvironmental pH (pH 6.8) then the endo/lysosomal pH (pH
4.5) successively.
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Supramolecular polymers have significant potential application in drug delivery due to their
reversible monomer-to-polymer transitions. Fig. 5 shows the molecular unit designed to
form a supramolecular architecture 35. The pair is a peptide amphiphile monomer composed
of three segments: a biological signal-bearing sequence, an amino acid-contained domain,
and a hydrophobic alkyl tail. These monomers can form a cylindrical aggregate where
twisted β sheets (red) collapse through hydrophobic interactions among alkyl chains,
resulting in high signal densities. The blue regions represent water domains present in the
assembly interior.
2.3 Challenges in Nanoparticle Development

Author Manuscript

There are many challenges that arise in the early and late stage development of medical
nanoparticles that are either nonexistent or minimal in non-nanoparticle based therapies 36.
The primary driver of these issues is the hierarchical and non-uniform nature of
nanoparticles, which means that a small change in a single property can have outsized
effects on the pharmacokinetics or therapeutic efficacy of the particle. As an example, one
common issue is maintaining a narrow distribution of particle size. For most applications, a
particle size under 200nm is desirable. With a broad normal distribution of sizes, this means
that often the average particle must be too small to be useful in order to limit the number of
particles over 200nm. It is thus desirable to have a manufacturing process that ensures a
narrow size distribution.

Author Manuscript

In addition, many unique challenges can arise during the trial and production stages of the
nanoparticle. Oftentimes, a procedure for nanoparticle formation that works in a lab setting
will not work in a factory, and the synthesis steps must be completely reworked. In a factory,
the variation in nanoparticle structure must be smaller, the yield must be higher, and the
synthesis must be more sterile than what is acceptable in a lab. All of these things can make
a particle unviable to produce even if it works. If a particle is sold, it must be shelf-stable,
which means that it both will not degrade in solution and that it will not clump over time, as
nanoparticles often do. Finally, nanoparticles face extra regulatory challenges as their
toxicity is much more difficult to determine than that of a small molecule. This greatly
increases the time and cost of clinical trials. These challenges combined mean that it is
always prudent to consider questions of scalability and reproducibility even at the earliest
stages of development to prevent failure at a later stage.

3. Cancer cell targeted drug delivery
3.1 Mechanism of cancer cell targeted drug delivery

Author Manuscript

Cancer cells are otherwise normal cells with unique mutations in genes regulating growth,
which cause them to divide uncontrollably and give them the ability to metastasize 37.
Cancer cells successfully compete with normal cells for oxygen, glucose, and amino acids
for division and growth, but a tumor can only grow to about 2mm3 without forming blood
vessels (angiogenesis) 38–40. There are more than one hundred types of cancer, more than
85% of which are solid 40. Current treatment includes surgery, radiotherapy, chemotherapy,
hormone therapy, and immunotherapy 40. However, the inability of drugs to specifically
target cancer cells hinders most treatment 2,41,42. It is often quicker and cheaper to design a
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more effective way to better target an existing drug than to develop an entirely new one.
Drug delivery targeting is classified as passive, active, or physical, and can target organs,
cells, or organelles. Organelle targeting is an especially promising field of research, as many
cancers specifically affect a single one, and certain organelles provide alternative paths for
drug localization.
3.2 Passive targeting nanocarrier systems
Drugs delivered intravenously tend to evenly disperse throughout the body. However, tumor
cells tend to take up particles of a certain size to a greater degree than healthy cells due to a
combination of leaky tumor blood vessels and faulty particle screening. This is known as the
enhanced permeation and retention (EPR) effect (Fig. 6) and is the mechanism behind
passive targeting 43.

Author Manuscript

The EPR effect is influenced by NP properties including particle size, shape, and surface
charge, and it in turn influences circulation time, penetration speed, and intracellular
internalization 44-45. For example, phagocytic cells favor the uptake of larger particles, while
non-phagocytic cells favor the uptake of smaller particles 46. It has been consistently shown
that PEGylated nanoparticles smaller than 100nm have reduced plasma protein adsorption
on their surface and reduced hepatic filtration 47. NPs with a negative surface charge will
circulate longer in blood, but positively charged NPs are more readily taken up by cancer
cells (which have negative surface charge) 8–10,48–50. In order to clarify the influence of
shape on the cellular uptake of PEGylated NPs, Liu et al, performed large scale molecular
simulations to study differently shaped NPs with identical surface area, ligand-receptor
interaction strength, and PEG grafting density (Fig. 7) 51. They found that spheres exhibited
the fastest internalization rate, followed by cubes, while rods and disks were the slowest.

Author Manuscript

Delivery platforms include liposomes 4, polymeric micelles 5,6, targeted polymer drug
conjugates 7, and dendrites. They all consist of macromolecule collections in which drugs
are dissolved, entrapped or conjugated to the surface 54. Several liposomal drug delivery
systems have received clinical approval, including ones for doxorubicin and daunorubicin.
An albumin-bound nanoparticle carrying paclitaxel, abraxane, was also approved by FDA
for breast cancer treatment 55.
Despite the EPR effect, more than 95% of passively targeted NPs fail to reach the tumor
when administered intravenously 48. Targeting can be greatly improved by locally
controlling drug release at the site of the tumor. This can be triggered through changes in the
microenvironment (pH, temperature, or enzymatic) or through external stimuli (light,
electric fields, magnetic fields, or ultrasound) directed at the tumor site 56–58.

Author Manuscript

An alternative way to improve the uptake of NPs, both passive and active, has been to
functionalize their surfaces with cell-penetrating peptides (CPPs). It has been found that
certain short (~30 amino acids) peptide sequences can pierce cell membranes and transport
drug cargo into a cell. These CPPs can be attached to micelles, liposomes, and other types of
NPs 59. Certain CPPs can also act as drug carriers on their own, carrying small molecules
and short stretches of DNA into cells 59. Most CPPs are amphiphilic, with a net positive
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charge. Because they are shaped similar to lysing peptides, certain CPPs can exert unwanted
toxic side effects.
3.3 Active targeting
Active targeting uses ligands bound to the NP surface to improve their uptake selectivity.
These ligands can react with target cells and will often protect NPs from enzyme
destruction. Ligands with a high binding affinity to the target cell will strongly increase
delivery efficiency. The most basic form of active targeting involves functionalizing a NP
with a ligand that binds to a molecule overexpressed on cancer cells. The issue with this, of
course, is that healthy cells still express the same molecule, and as healthy cells greatly
outnumber tumor cells most of the NPs miss their target. This issue can be mitigated by
using multiple ligands, or by using ligands of different types.

Author Manuscript

Approaches to identify potential receptors in and on cancer cells include in vivo phage
screening and aptamer screening 60. Using in vivo phage screening, F3 was discovered to
bind well with nucleolin 61, which is present at tumor cell surfaces and in tumor endothelial
cells. The cytoplasmic proteins annexin1 62, plectin-1 63, and p32 protein 64 were also found
through in vivo phage screening. By studying the expression of the known cell surface
receptors in tumor vessels, other molecular markers can be detected. For example, ∂vß3,
∂vß5 integrins, and ED-B were discovered in angiogenic vessels using this principle 65–68.
Gene expression analysis has also been used to discover overexpression of collagen in tumor
endothelial cells 69 A detailed review on various markers and their discovery methods was
given by Ruoslahti 60.

Author Manuscript
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Many antibodies have been approved for use in clinical treatment by the FDA, such as
rituximab, Ipilimumab, and trastuzumab 70. Antibodies are among the most studied ligands
because of their high specificity and availability. An antibody conjugated dendrimer was
found to bind exclusively to human prostate adenocarcinoma (LNCaP) cells that express
PSmA(J591) 26. Although antibodies have many merits, they are difficult to conjugate to
NPs, result in a short circulation time, and are expensive. Peptides are a promising
alternative, as they are smaller, simpler, more stable, and easier to produce. Among peptides,
RGD is often used due to its strong binding with αvβ3 integrin receptors. Nucleic acid base
aptamers combine the advantages of both antibodies and peptides, but they degrade quickly.
Other small molecules can also be used as ligands, such as folic acid for folate receptors 71.
Such molecules are small, stable, and easy to produce. Unfortunately, ligand detection for
relevant substrates is challenging. Even with proper binding ligands and receptors, binding
incompatibility can limit therapeutic efficiency. Multiple ligands with different charges can
increase overall the binding affinity, but the limited binding ability and capacity of receptors
will govern the quantity and quality of the binding. For instance, overly strong binding can
actually reduce tumor penetration, hinder selectivity, and lead to an overdose of carriers 72.
Active targeting alters the natural distribution patterns of a carrier, directing it to a specific
organ, cell, or organelle. In contrast, passive targeting relies on the natural distribution of the
drug and the EPR effect. Both of these processes depend on blood circulation and the
location of initial drug delivery. However, no actively targeted NPs are commercially
available currently.
J Nanomater. Author manuscript; available in PMC 2016 July 07.
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3.4 Physical targeting

Author Manuscript

Physical targeting navigates drugs to cancer cells using external stimulation, such as
radiation or magnetic fields. Photothermal therapy is often used because of its relatively few
side effects. Photothermal therapy uses NPs that once delivered, efficiently convert near
infrared light energy to heat, killing cancer cells. Currently, most research is being carried
out using gold nanoparticles because they can be well controlled and have low toxicity.
Their SPR effects can be tuned by shape, size, and thickness to maximize excitation and
focus on a specific wavelength. According to a previous report, gold nanoparticles are
already being tested in animals 73.
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Photothermal agents other than gold have also been explored. Carbon nanotubes show strong
absorbance in near infrared region 31, and it has been demonstrated that photothermal
hyperthermia using them can inhibit G2-M cell cycles 32. Graphene has also been used in
photothermal drug delivery. Functionalized graphene oxide with polymer conjugates is pH
sensitive and its photothermal effect can cause cell death 30. Silica-coated graphene nanosheets functionalized with hydrophilic polyethylene glycol have also been used to deliver
doxorubicin 25. In the cases of carbon nanotubes and graphene oxide, pH and heat are used
to initiate drug release.
One limitation to photothermal therapy is that cancer cells are often tolerant to
environmental stress, for example with heat shock proteins that prime the cell against further
damage 74. Nanoparticle-free radiation therapies are quite common, however. High-energy
x-ray or gamma radiation is cytotoxic and can kill cells in specific regions 75. The details of
radiation therapy have been reviewed by Stacy 75.
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Magnetic hyperthermia uses the heat energy produced by magnetic nanoparticles oscillating
in a magnetic field. The distance between magnetic nanoparticles and target cells, sensitivity
to magnetic fields, and magnetic field strength all affect heat energy production and correlate
to therapeutic effects. Magnetic NPs typically consist of four parts: NPs, protective agents,
biomolecules, and surface agents. They are usually synthesized based on magnetite (Fe3O4),
maghemite, cobalt, or nickel. Among them, iron oxides are most used due to its
biocompatibility and shape controllability.

Author Manuscript

Magnetic NPs are usually coated with functional polymers like carbohydrates and proteins
to protect against corrosion and potential toxin release. However, some polymers’
mechanical strength and selectivity are not easy to control, so organic linkers are often used
to create electrostatic interaction. Replacing ions and changing the pH of the immediate
environment can also modify the binding strength of magnetic particles. Both photothermal
therapy and magnetic hyperthermia can be done in vivo and in vitro, and several clinical
trials have been performed 76. Unlike active targeting or physical targeting alone, this
combination can effectively promote NP internalization by tumor cells 77.
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4. Modeling applications in drug delivery and nanoparticle device design
4.1 Models and their applications in the field
Drug delivery NPs become complex because the pharmacokinetic properties of the drug
itself must be fully understood as well as all parts of the delivery system. NPs can be
affected by many parameters, including platform (liposomes, polymeric micelles, polymer
drug conjugates, dendrites), physical parameters (size, shape), and surface chemistry. On its
way to the target, the NP must pass through and interact with multiple biological barriers,
including those in the bloodstream, at the site of the tumor, at the surface of the cell, and
several within the cell. In addition, the efficacy of a NP is highly dependent on individual
patient conditions.

Author Manuscript

Because nanoparticle research is complex, with many variables and costly experiments, it is
an excellent candidate for computer simulations. Simulations can both screen drug and
carrier candidates and provide design insights towards entirely new NPs. Theoretical and
computational modeling can be used for any of the drug delivery processes previously
reviewed to provide solutions for optimized geometry, surface chemistry, or other properties.
For instance, continuum based modeling is used to study transport and dissolution,
molecular dynamics are used for cell interaction, and stochastic approaches such as Monte
Carlo simulations can be used to calculate random variables and take uncertainties into
account for each patient.
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Continuum Modeling—Transport modeling of NPs through the vascular network is
challenging due to vastly different blood vessel diameters, which range from centimeters for
larger vessels to microns for capillaries. Advection-diffusion models are used for transport in
the larger vessels, where blood is modeled as a simple Newtonian fluid 78-79. In the
microvascularture, a convection-diffusion-reaction model was developed for nanoparticle
concentration studies. G. Fullstone 80 used flexible large-scale agent based modeling
(FLAM) coupled with computational fluid dynamics (CFD) to study NP distribution in
capillaries. In the microvasculature, red blood cells aid NP dispersion to the vessel walls and
modify the EPR effect. It was reported that larger NPs (submicron size) are more likely to be
pushed to the vessel walls than smaller NPs, which in turn gives them a greater chance of
permeating through diseased vasculatures to reach the target cells 80. NP adhesion with
endothelial cells modeled with IMEFEM suggests that NP shape affect adhesion, with
spherical NPs having a lower lateral drift velocity compared with ellipsoids. A NPs binding
probability can be simulated by randomly assigning initial positions of nanoparticles at the
channel inlet, applying a Brownian adhesion dynamics model, conducting a number of
independent trials, calculating the average of number of bonded nanoparticles, and then
normalizing the total number of nanoparticles for a certain depletion layer thickness and
shear rate. Nanoparticle deposition and distribution patterns inside the blood vessel network
can also be simulated using a continuum model 12. Saltzman and Radomsky 81 developed a
diffusion based kinetics model to study drug release problems in brain tissue. Their
prediction was validated with drug distribution profiles gained through in vitro experiments.
Pressure, velocity, and blood chemistry will all affect the transport of NPs and can lead to
premature deformation or release. An accurate prediction of these parameters is thus critical
J Nanomater. Author manuscript; available in PMC 2016 July 07.

Yu et al.

Page 11

Author Manuscript

to design stable NPs. Factors that affect NP deformation and release include blood flow
velocity, shear rate, bonding energy, and porosity. It has been shown that NPs can be
modeled using a combination of diffusion, swelling, and erosion 79,82,83. Because of
possible swelling and erosion during circulation, one must assume a dynamic boundary for
the continuum models during the release process 12. Finite element analysis can be used to
solve these models.
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Molecular Modeling—Molecular modeling can be used to understand the size, shape,
and charge distribution within a system. It is based on interactions between atoms and
molecules for a fixed time period. Free energy minimizations of the system can generate a
numerical solution for complex system properties. Hence, it can be used in animating
molecular motion and elucidating both the uptake process and the influence of molecular
structure, NP size, shape, and surface chemistry. Depending on how potential energies are
calculated, various molecular modeling methods, including empirical methods, ab initial
quantum mechanical methods, classic molecular dynamics, and coarse grain molecular
dynamics can be used to understand drug-carrier and carrier-medium interactions 84.

Author Manuscript

Empirical molecular descriptors relying heavily on experimental data fitting can be used to
predict physical properties such as drug solubility, and the diffusion coefficient, which often
results in complicated artificial parameters. By deriving the theoretical molecular descriptors
from compound chemical structures, limitations of experiment data can be resolved.
Quantum mechanical ab initio method is a useful tool for property calculations and higherlevel model calibrations by considering the electronic degrees of freedom. It uses quantum
mechanical methods such as the density functional theory to determine information about
electronic behavior. It can simulate a few hundred atoms without any experimental input and
output information otherwise unavailable, such as the electronic state. Adhikari et al. 85
studied RGD-4C peptide electronic structure, partial surface charge distribution, and
dielectric response with ab initio quantum mechanical methods and shed light on the
peptide-∂vß3 integrin receptor interaction. It is particularly useful for the study of bond
breaking and formation. Unfortunately this method is very complex and computationally
intensive to simulate large systems, or to simulate for significant lengths of time.

Author Manuscript

Classical molecular mechanical simulations are less time consuming compared with the ab
initial quantum mechanical methods. The potential energy is relatively easy to calculate, so
they can be used for larger systems and a longer period of time. Coarse-grained molecular
dynamics are used for large systems and for simulations that run on a timescale of larger
than 1ms. Instead of calculating all the atoms in the system, subunits are selected for system
energy calculations. Model parameters need to be fitted with experimental data, so the
accuracy is limited by the availability of data. Loverde, et al. used coarse grain molecular
dynamics to study the shape effect of Worm-like PEG-PCL micelles in drug delivery. It was
found that PEG and the PEG-PCl interface play am important role in drug release 86. Coarse
grain MD can also be used for cellular uptake process simulations with multi-wall CNT. Dr.
Gao et al. have modeled the uptake process with CGMD by assuming immobile ligands and
diffusive receptors 87. They predicted a critical NP size for endocytosis consistent with
experimental results 87. The studies of Yang and Ma 88 and Ying Li 89 both show that shape
and initial orientations affect the endocytosis process. Endocytosis is governed by the
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bending energy of the cell membrane and the ligand-receptor binding energy. Bao and
Bazilevs 90 also used large-scale coarse-grained MD to understand how PEGylation affects
NP endocytosis. They found that the repulsive interaction energy between grafted chains and
cell membranes is larger than the membrane bending energy through endocytosis. Optimal
grafting density is also predicted for ligand-receptor interactions.
Stochastic Modeling—Each patient's physical and pathological conditions are
different, including blood flow rates, red blood cells, vascular networks and receptor
densities on the tumor cell surface. Even for the same person, these parameters can change
over time. It is thus crucial to consider uncertainties for the parameters in models. Simply
using average values can lead to unacceptable errors in the modeling and design of a NP
platform. Monte Carlo methods are particularly good options when dealing with these
parameters uncertainties 12.

Author Manuscript

Monte Carlo method use random generators from certain probability distributions to
artificially produce samples repetitively and calculate mean and variance of the samples. The
In fact, Monte Carlo simulations have been used to study the interaction between ligandbound NPs with both tumor cells and healthy cells. Many parameter values have been
considered as inputs in order to understand their effects 91, and it was found that multiple
weak reversible ligand receptors binding is the most important variable in selective targeting.
Liu et al. used Monte Carlo simulation to understand the effect of surface functionalization
of NPs on its binding to endothelium. They found that antibody coverage is the key
parameter for binding process to occur.92 Recently, Ying Li, etc. quantified the uncertain
dispersion coefficient of NPs during microvascular drug transport process with Bayesian
calibration method. 89

Author Manuscript
Author Manuscript

Linking of Multiple Length Scales in Modeling—Drug delivery takes place across
various time and spatial scales. NP circulation, endocytosis, and drug release can each be
modeled with appropriate computational methods mentioned above. However, to simulate
the entire system from drug to patient remains a challenging problem. There are some
reports on multiscale model frameworks shown in (Fig.8). The input of these systems tends
to be things like drug attributes, delivery system characteristics and patient specific
information. Monte Carlo methods and atomic calculations such as molecular dynamics can
be used to predict physical parameters, diffusivity, and solubility. At the patient scale, MRI
images taken from experiments can be used to provide the geometry of the vascular network.
After providing initial concentration and location of injected NPs, the concentration profile
of NPs in the vascular system can be simulated with immersed FEM analysis. Coarsegrained MD can use the concentration information together with the drug carrier architecture
to simulate the interaction between NPs and target cell membranes. When the information is
passed from one model to another, uncertainties are also passed along. Ying Li provided a
good example of how to deal with error propagation when connecting models together. By
coupling different scales together, the drug delivery optimization problem can get much
closer to the right solution 89.
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4.2 Challenges and Limitations in Modeling
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Computational modeling has not been widely used in pharmaceutical industry for drug
delivery design due to its limited predictability and accuracy. Most current approaches are
agent-based empirical models. Mechanism based models are unable to realistically describe
biological and chemical interactions and delivery processes. The fundamental mechanisms
of each process needs to be better understood, and can be aided by smarter experimental
design. Each of the computational models has its limitations. Most of the current
mechanistic models focus on a particular process instead of coupling with each other to
simulate the entire process from drug to patient. Linking models of different temporal and
spatial scales is challenging but will provide the greatest benefit in terms of accuracy.

Author Manuscript

Mechanistic models require high quality data for parameter estimation, model calibration,
validation, and error analysis. To track molecules and nanoparticles in living cells and
tissues over time is challenging, so in vitro data for more physiologically realistic
simulations is also needed. Repeated experiments are needed to build physiological and
delivery system variable statistical distributions. Uncertainty quantification and updating is
required for connecting lower scale level atomistic models with higher scale level continuum
models as error from one part of the simulation can propagate leading to an unacceptable
solution.

5 Conclusion and Future Works

Author Manuscript

NPs are good candidates for targeted drug delivery carriers. They are widely available, easily
functionalized with good biocompatibility and stability. Concentrated doses of toxic drugs
can be encapsulated and delivered by the nanoparticles directly to the tumor site. Currently
there are three delivery strategies: Passive targeting, which relies on the EPR effect; Active
targeting, which uses ligand-receptor interactions for more selective drug delivery; and nextgeneration photothermal and magnetic hybrid NPs, where drugs release is controlled in both
time and location using heat generated by the photothermal or magnetic nanoparticle.
Physical targeting is still at the clinical trial stage.

Author Manuscript

NPs can self-assemble into different structures, including amphiphilic micelles and
liposomes, as well as more exotic rotaxanes, dendrimers, and metal core particles. Each of
these particles has specific strengths and weaknesses and is suitable for the delivery of
different therapies to different regions. The choice of a nanoparticle has much to do with the
application in mind- there is not yet a gold standard. Most typical NPs used as drug delivery
carriers are micelles and liposomes, but there is increasing research into other particles.
Rotaxanes can release cargo in response to a tailored stimulus, while dendrimers can
sometimes maximize surface area and cargo capacity when compared with simple spherical
structures. In addition, metal-core particles are a good choice for physical and combination
physical-active or physical-passive targeting.
Experimental development of these NPs is challenging, as size, shape, and surface charge
must all be controlled to carry drugs to the target site. Inappropriate physical parameters not
only can compromise drug delivery efficacy but also cause serious side effects. Developed
NPs have to be tested in both living cells and tissue first before they can be moved to in vivo
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tests. Environmental differences can also impact drug delivery efficacy. Due to the
complexities of the drug delivery process and the large amount of uncertainty involved,
computational modeling is mostly applied for NP design optimization. Currently, they are
not used widely in the pharmaceutical industry due to their poor predictability. Most models
only focus on specific processes in drug delivery instead of full simulations from the drug to
the patient scale. Multiscale modeling across different temporal and spatial scales is rare.

Author Manuscript

In the future, NP design can be better guided by multiscale modeling. However, experiments
also provide needed data for model calibration, validation, and help to understand the
mechanisms unique to each drug delivery process. Multiscale models that take in
personalized data, such as MRI scanned vascular network image, genome, family history,
targeted cell receptor density, and the physical-chemical properties of NPs should be further
improved and validated in clinical settings. Collaborative work of computation and
experiment is already used for more efficient nanocarrier design. Shi, et al 93 used molecular
docking/MD simulation to screen building blocks for nanocarrier synthesis. Their models
were validated with experimental synthesis and evaluations of nanocarrier library. Jiang, et
al 94 employed multiscale modeling together with experiments to understand the building
blocks’ role in telodendrimer self-assembly process. Recently, microchip device
development has become another direction to simulate a tumor's microenvironment and test
the effectiveness of NPs for targeted drug delivery 95,90. Device design can also be
facilitated by computational models, which will further advance the development of NPs for
drug delivery.
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Fig. 1.

Schematic contrast of drug biodistribution after injection of free drug (A) and drug-loaded
NPs (B).
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Schematic of two types of amphiphilic nanoparticles, liposomes and micelles. Liposomes
have a double layer and a hydrophilic core, while the core of micelles is hydrophobic.
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Fig. 3.

Structures of novel nanoparticles. A) Polyrotaxane NPs are assembled from cyclical
molecules threaded around a long polymer chain. Hydrophilic ends are added to the chain in
order to induce self-assembly. Drugs are then added to the finished NP. Adapted with
permission from 24. B) Graphene functionalized with shielding molecules and ligands.
Adapted with permission from 25. C) Carbon nanotube schematic. D) Dendrimer schematic.
E) Metal-core photothermal NP schematic.
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Fig. 4.

Schematic representation of the disulfide cross-linked micelles formed by oxidization of
self-assembled thiolated telodendrimer PEG5k-Cys4-L8-CA8 27. Schematic representation of
the telodendrimer pair [PEG5k-(boronic acid or Catechol)4-CA8] and the resulting boronate
crosslinked micelles (BCM) triggered by mannitol and/or acidic pH values 28.
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Fig. 5.

Molecular representation of monomer and the corresponding supramolecular polymer
formed after their aggregation through specific interactions 35.
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Fig. 6.

Schematic illustration of enhanced permeation and retention (EPR) effect.
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Fig. 7.

Differently shaped NPs: sphere, rod, cube and disk. The top shows the transmission electron
microscopy images of these NPs.5253 The bottom shows the PEGylated NPs with grafting
density 1.6 chains per nm2 in molecular simulations 51.
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Fig. 8.

A multiscale-modeling framework for drug delivery processes. Reorganized with permission
from 12.
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